GNLX NASDAQ
Genelux Corporation
1W: +0.7%
1M: +1.7%
3M: +17.1%
YTD: -35.2%
1Y: -15.0%
3Y: -87.8%
$2.92
-0.03 (-1.02%)
Weekly Expected Move ±4.8%
$3
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$130.9M
52W Range2.29-8.535
Volume145,446
Avg Volume170,869
Beta0.57
Dividend—
Analyst Ratings
Company Info
CEOThomas D. Zindrick
Employees26
SectorHealthcare
IndustryBiotechnology
IPO Date2023-01-26
Websitegenelux.com
2625 Townsgate Road
Westlake Village, CA 91361
US
Westlake Village, CA 91361
US
858 483 0024
About Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Latest News
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
Genelux GAAP EPS of -$0.20
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
FY2029 Earnings Estimate for Genelux Issued By HC Wainwright
Genelux GAAP EPS of -$0.86 misses by $0.01
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Smither John W | S-Sale | 12,000 | $2.91 | 2026-07-01 |
| Pulisic Matthew | A-Award | 278,906 | — | 2026-06-16 |
| Groen Eric | A-Award | 233,957 | — | 2026-06-16 |
| Cappello Joseph | A-Award | 174,841 | — | 2026-06-16 |
| Tyree James L | A-Award | 28,409 | — | 2026-06-16 |